ATI-5923

DRUG2 trials

Sponsors

ARYx Therapeutics

Conditions

Atrial FibrillationAtrial FlutterCardiomyopathyMyocardial InfarctionVenous Thromboembolic Disease

Phase 2

Study of a New Anticoagulant Drug in Patients With Atrial Fibrillation

CompletedNCT00431782

ARYx TherapeuticsAtrial Fibrillation

Start: 2006-12-31End: 2007-10-31Target: 60Updated: 2007-11-08

Comparison of ATI-5923, a Novel Vitamin K Antagonist, With Warfarin in Patients Requiring Chronic Anticoagulation

ARYx TherapeuticsAtrial Fibrillation, Atrial Flutter, Cardiomyopathy +2

Start: 2008-05-31End: 2009-06-30Target: 600Updated: 2010-02-02